| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | REGULATABLE CHIMERIC ANTIGEN RECEPTOR | US15105074 | 2014-12-19 | US20160311907A1 | 2016-10-27 | Jennifer Brogdon; Boris Engels; David Jonathan Glass; Brian Granda; John Hastewell; Andreas Loew; Joan Mannick; Michael Milone; Leon Murphy; William Raj Sellers; Huijuan Song; Brian Edward Vash; Jan Weiler; Qilong Wu; Li Zhou |
| Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease. | ||||||
| 2 | 調節可能キメラ抗原受容体 | JP2016559487 | 2014-12-19 | JP2017502690A | 2017-01-26 | ジェニファー・ブログドン; ボリス・エンヘルス; デイビッド・ジョナサン・グラス; ブライアン・グランダ; ジョン・へイストウェル; アンドレアス・レーヴ; ジョアン・マニック; マイケル・ミローン; レオン・マーフィー; ウィリアム・ラジ・セラーズ; ソン・ホイジュエン; ブライアン・エドワード・バッシュ; ヤン・ヴァイラー; チーロン・ウー; リー・ジョウ |
| 調節可能キメラ抗原受容体(RCAR)に関し、ここで、RCARの細胞内シグナル伝達または増殖が、免疫応答を提供するためにRCAR発現細胞で使用するために最適化されるように制御されている組成物および方法が提供される。例えば、RCARは、二量体化分子の存在により、細胞内シグナル伝達ドメインを細胞外認識成分、例えば、抗原結合ドメイン、阻害カウンターリガンド結合ドメインまたは共刺激ECDドメインと結合できる二量体化スイッチを含む。RCARを、所望の抗原標的に特異的であり、疾患の処置に使用する適切な抗原結合ドメインを含むように操作し得る。 | ||||||
| 3 | REGULATABLE CHIMERIC ANTIGEN RECEPTOR | EP14872734 | 2014-12-19 | EP3087101A4 | 2017-12-06 | BROGDON JENNIFER; ENGELS BORIS; GLASS DAVID JONATHAN; GRANDA BRIAN; HASTEWELL JOHN; LOEW ANDREAS; MANNICK JOAN; MILONE MICHAEL; MURPHY LEON; SELLERS WILLIAM RAJ; SONG HUIJUAN; VASH BRIAN EDWARD; WEILER JAN; WU QILONG; ZHOU LI |
| Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease. | ||||||
| 4 | REGULATABLE CHIMERIC ANTIGEN RECEPTOR | EP14872734.0 | 2014-12-19 | EP3087101A1 | 2016-11-02 | BROGDON, Jennifer; ENGELS, Boris; GLASS, David Jonathan; GRANDA, Brian; HASTEWELL, John; LOEW, Andreas; MANNICK, Joan; MILONE, Michael; MURPHY, Leon; SELLERS,William Raj; SONG, Huijuan; VASH, Brian Edward; WEILER, Jan; WU, Qilong; ZHOU, Li |
| Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease. | ||||||
QQ群二维码
意见反馈
意见反馈